Treating Morbid Obesity in Cirrhosis: A Quest of Holy Grail

Overview

Journal World J Hepatol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2015 Dec 16

PMID 26668693

Citations 8

Authors

Naveen Kumar

Narendra Singh Choudhary

Affiliations

Soon will be listed here.

Abstract

The problem of obesity is increasing worldwide in epidemic proportions; the situation is similarly becoming more common in patients with cirrhosis which negatively affect the prognosis of disease and also makes liver transplantation difficult especially in the living donor liver transplantation setting where low graft to recipient weight ratio negatively affects survival. Treatment of obesity is difficult in cirrhosis due to difficulty in implementation of lifestyle measures, limited data on safety of anti-obesity drugs and high risk of surgery. Currently approved anti-obesity drugs have limited data in patients with cirrhosis. Bariatric surgery remains an option in selected compensated cirrhotic patients. Endoscopic interventions for obesity are emerging and are quite promising in patients with cirrhosis as these are minimally invasive. In present review, we briefly discuss various modalities of weight reduction in obese patients and their applicability in patients with cirrhosis.

Citing Articles

Management and Risks Before, During, and After Liver Transplant in Individuals With Obesity.

Alqahtan S, Brown R Gastroenterol Hepatol (N Y). 2023; 19(1):20-29.

PMID: 36865816 PMC: 9972654.

Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease.

Yin X, Guo X, Liu Z, Wang J Int J Mol Sci. 2023; 24(3).

PMID: 36769165 PMC: 9917647. DOI: 10.3390/ijms24032844.

Sarcopenia in the Cirrhotic Patient: Current Knowledge and Future Directions.

Warner Ii E, Satapathy S J Clin Exp Hepatol. 2023; 13(1):162-177.

PMID: 36647414 PMC: 9840086. DOI: 10.1016/j.jceh.2022.06.005.

Is Fasting Good When One Is at Risk of Liver Cancer?.

Minciuna I, van Kleef L, Stefanescu H, Procopet B Cancers (Basel). 2022; 14(20).

PMID: 36291868 PMC: 9600146. DOI: 10.3390/cancers14205084.

A narrative review of nutritional abnormalities, complications, and optimization in the cirrhotic patient.

Warner 2nd E, Aloor F, Satapathy S Transl Gastroenterol Hepatol. 2022; 7:5.

PMID: 35243114 PMC: 8826036. DOI: 10.21037/tgh-20-325.

References

Jou J, Choi S, Diehl A . Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis. 2008; 28(4):370-9. DOI: 10.1055/s-0028-1091981. View

Konishi I, Hiasa Y, Tokumoto Y, Abe M, Furukawa S, Toshimitsu K . Aerobic exercise improves insulin resistance and decreases body fat and serum levels of leptin in patients with hepatitis C virus. Hepatol Res. 2011; 41(10):928-35. DOI: 10.1111/j.1872-034X.2011.00833.x. View

Genco A, Bruni T, Doldi S, Forestieri P, Marino M, Busetto L . BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients. Obes Surg. 2005; 15(8):1161-4. DOI: 10.1381/0960892055002202. View

Gentile C, Pagliassotti M . The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem. 2008; 19(9):567-76. PMC: 2551556. DOI: 10.1016/j.jnutbio.2007.10.001. View

Choudhary N, Saigal S, Saraf N, Puri R, Soin A . Innovative approach using an intragastric balloon for weight loss in a morbidly obese patient undergoing liver transplantation. Liver Transpl. 2012; 19(2):235. DOI: 10.1002/lt.23567. View

Greenway F, Fujioka K, Plodkowski R, Mudaliar S, Guttadauria M, Erickson J . Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010; 376(9741):595-605. DOI: 10.1016/S0140-6736(10)60888-4. View

Armstrong M, Adams L, Canbay A, Syn W . Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2013; 59(3):1174-97. DOI: 10.1002/hep.26717. View

Chen Y, Wang X, Wang J, Yan Z, Luo J . Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer. 2012; 48(14):2137-45. DOI: 10.1016/j.ejca.2012.02.063. View

Day C . From fat to inflammation. Gastroenterology. 2006; 130(1):207-10. DOI: 10.1053/j.gastro.2005.11.017. View

10.

Gras J . Cetilistat for the treatment of obesity. Drugs Today (Barc). 2014; 49(12):755-9. DOI: 10.1358/dot.2013.49.12.2099318. View

11.

Lin M, Tavakol M, Sarin A, Amirkiai S, Rogers S, Carter J . Laparoscopic sleeve gastrectomy is safe and efficacious for pretransplant candidates. Surg Obes Relat Dis. 2013; 9(5):653-8. DOI: 10.1016/j.soard.2013.02.013. View

12.

ONeil P, Smith S, Weissman N, Fidler M, Sanchez M, Zhang J . Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012; 20(7):1426-36. DOI: 10.1038/oby.2012.66. View

13.

Hickman I, Jonsson J, Prins J, Ash S, Purdie D, Clouston A . Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004; 53(3):413-9. PMC: 1773957. DOI: 10.1136/gut.2003.027581. View

14.

Angulo P . Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl. 2006; 12(4):523-34. DOI: 10.1002/lt.20738. View

15.

Garcia-Pagan J, Santos C, Barbera J, Luca A, Roca J, Rodriguez-Roisin R . Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology. 1996; 111(5):1300-6. DOI: 10.1053/gast.1996.v111.pm8898644. View

16.

Scott L . Liraglutide: a review of its use in the management of obesity. Drugs. 2015; 75(8):899-910. DOI: 10.1007/s40265-015-0408-8. View

17.

Padwal R, Kezouh A, Levine M, Etminan M . Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond). 2007; 31(10):1567-70. DOI: 10.1038/sj.ijo.0803631. View

18.

Greenway F, Dunayevich E, Tollefson G, Erickson J, Guttadauria M, Fujioka K . Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009; 94(12):4898-906. DOI: 10.1210/jc.2009-1350. View

19.

Powell A, Apovian C, Aronne L . New drug targets for the treatment of obesity. Clin Pharmacol Ther. 2011; 90(1):40-51. DOI: 10.1038/clpt.2011.82. View

20.

Campillo B, Bories P, LELUAN M, Pornin B, Devanlay M, FOUET P . Short-term changes in energy metabolism after 1 month of a regular oral diet in severely malnourished cirrhotic patients. Metabolism. 1995; 44(6):765-70. DOI: 10.1016/0026-0495(95)90190-6. View